entertainment -WSS

entertainment

author：hotspot 2025-09-30 17:28:53 - browse：6

Illustration of a human hand beneath a projection of digital files to visualize humans' role in AI technology — Adobe

Developers of artificial intelligence models slowly making their way into medicine have long parried ethical concerns with assertions that clinical staff must review tech’s suggestions before they are acted on. That “human in the loop” is meant to be a backstop preventing potential medical errors conjured up by a flawed algorithm from harming patients.

And yet, industry experts warn that there’s no standard way to keep humans in the loop, giving technology vendors significant latitude to market their AI-powered products as helpful professional tools rather than as autonomous decision-makers.

Health record giant Epic is piloting a generative AI feature that drafts responses to patients’ email queries, but clinical staff must review the suggestions before they are sent out, the company has said. A flurry of AI-guided ambient documentation startups can rapidly transcribe and summarize patient visits and populate patients’ medical charts, but they require doctors and nurses to OK the generated entries first. Products predicting health risks — like overdose or sepsis — show up as flags in medical record software, and it’s up to clinicians to act on it.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： All of Us, NIH's precision medicine initiative, gets a big boost

focus

Wikipedia

WSS

FDA endorses new sterilization method for medical devices

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

A pediatrician calls for Congress to pass the child tax credit deal

High breast density mammograms need follow

FDA sets aggressive timeline for overhauling inspection procedures

Pumping milk in bathrooms at health conferences is common

focus

entertainment

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Medical leaders decry Supreme Court decision on affirmative action

Explaining an after

Trump demands the U.S. pay no more for drugs than other countries … again

High breast density mammograms need follow

Bright Health sells Medicare Advantage business to Molina

Update the Apgar Score to remove skin color

After affirmative action ruling, medical educators look to 'holistic review'

All of Us, NIH's precision medicine initiative, gets a big boost

entertainment

Future doctors need a strong humanities education

Coloradans with cystic fibrosis could lose access to Trikafta

High breast density mammograms need follow

Sarepta Duchenne therapy fails to meet primary endpoint in trial

To bolster infectious disease surveillance, genomics powerhouses team up

Gene therapy’s promise and the high cost of hope

focus

focus

Wikipedia

leisure time